Wide Ranks

CVAC

CureVac N.V.

2.87

Top Statistics
Market Cap 643 M Forward PE -5.63 Revenue Growth 90.50 %
Current Ratio 2.29 Trailing PE 5.86 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.78 Enterprise / Revenue 7.29 Price To Sales Trailing12 Months 9.78
Profitability
Profit Margins 0.00 % Operating Margins -493.58 %
Balance Sheet
Total Cash 202 M Total Cash Per Share 0.9030 Total Debt 39 M
Total Debt To Equity 10.37 Current Ratio 2.29 Book Value Per Share 1.68
All Measures
Short Ratio 901.00 % Message Board Id finmb_20786046 Shares Short Prior Month 4 M
Return On Equity -0.5430 City Tübingen Uuid 340ff847-a470-30d6-90e0-0760c5ece1e8
Previous Close 2.74 First Trade Date Epoch Utc 1 B Book Value 1.68
Beta 2.61 Total Debt 39 M Volume 771002
Price To Book 1.71 Fifty Two Week Low 2.21 Total Cash Per Share 0.9030
Total Revenue 65 M Shares Short Previous Month Date 1 B Target Median Price 4.73
Max Age 86400 Recommendation Mean 2.25 Sand P52 Week Change 0.3133
Operating Margins -493.58 % Target Mean Price 6.89 Net Income To Common -278430016
Short Percent Of Float 0.1100 Implied Shares Outstanding 224 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 631080 Average Volume10days 631080
Total Cash 202 M Next Fiscal Year End 1 B Revenue Per Share 0.2940
Held Percent Insiders 0.4526 Trailing PE 5.86 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.74 Target Low Price 2.36
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.84 Open 2.75
Free Cashflow -222099008 Dividend Yield 0.00 % Return On Assets -0.2452
Time Zone Short Name EST Trailing Eps 0.4900 Day Low 2.75
Address1 Friedrich-Miescher-Strasse 15 Shares Outstanding 224 M Price Hint 4
Target High Price 15.13 Website https://www.curevac.com 52 Week Change -0.4685
Average Volume 482464 Forward Eps -0.4400 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 219.40 % Is_sp_500 False
Regular Market Day High 2.93 Profit Margins 0.00 % Debt To Equity 10.37
Fifty Two Week High 6.30 Day High 2.93 Shares Short 4 M
Regular Market Open 2.75 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 7.29 Revenue Growth 90.50 % Shares Percent Shares Out 0.0197
Operating Cashflow -289852000 Currency USD Time Zone Full Name America/New_York
Market Cap 643 M Is_nasdaq_100 False Zip 72076
Quote Type EQUITY Industry Biotechnology Long Name CureVac N.V.
Regular Market Day Low 2.75 Held Percent Institutions 0.1887 Current Price 2.87
Enterprise To Ebitda -1.78 Financial Currency EUR Current Ratio 2.29
Gross Margins -131.00 % Industry Disp Biotechnology Number Of Analyst Opinions 6
Country Germany Float Shares 123 M Two Hundred Day Average 3.18
Enterprise Value 480 M Price To Sales Trailing12 Months 9.78 Forward PE -5.63
Regular Market Volume 771002 Ebitda -270342016 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
CureVac N.

V.

, a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).

It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.

CureVac N.

V.

was founded in 2000 and is headquartered in Tübingen, Germany.